Mycophenolate mofetil

Bezeichnung:Mycophenolate mofetil

CAS-Nr115007-34-6

Englisch Name:Mycophenolate mofetil

CBNumberCB2663335

SummenformelC23H31NO7

Molgewicht433.49

MOL-Datei115007-34-6.mol

Mycophenolate mofetil physikalisch-chemischer Eigenschaften

Löslichkeit	Practically insoluble in water, freely soluble in acetone, sparingly soluble in anhydrous ethanol.
BCS Class	2
InChI	InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
InChIKey	RTGDFNSFWBGLEC-SYZQJQIISA-N
SMILES	C12COC(=O)C=1C(O)=C(C/C=C(\C)/CCC(=O)OCCN1CCOCC1)C(OC)=C2C
CAS Datenbank	115007-34-6(CAS DataBase Reference)

Gefahreninformationscode (GHS)

Bildanzeige (GHS)
Alarmwort

Achtung
Gefahrenhinweise

H302：Gesundheitsschädlich bei Verschlucken.

H341：Kann vermutlich genetische Defekte verursachen.

H360：Kann die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen.

H370：Schädigt die Organe.

H410：Sehr giftig für Wasserorganismen mit langfristiger Wirkung.
Sicherheit

P201：Vor Gebrauch besondere Anweisungen einholen.

P202：Vor Gebrauch alle Sicherheitshinweise lesen und verstehen.

P260：Dampf/Aerosol/Nebel nicht einatmen.

P264：Nach Gebrauch gründlich waschen.

P264：Nach Gebrauch gründlich waschen.

P270：Bei Gebrauch nicht essen, trinken oder rauchen.

P273：Freisetzung in die Umwelt vermeiden.

P281：Vorgeschriebene persönliche Schutzausrüstung verwenden.

P301+P312：BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

P307+P311：BEI Exposition: GIFTINFORMATIONSZENTRUM oder Arzt anrufen.

P308+P313：BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

P321：Besondere Behandlung

P330：Mund ausspülen.

P391：Verschüttete Mengen aufnehmen.

P405：Unter Verschluss aufbewahren.

P501：Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Mycophenolate mofetil Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften
White or almost white, crystalline powder.
Verwenden
Inhibitor of nucleic acid synthesis; immunomodulator.
Verwenden
Mycophenolate Mofetil is an intermediate in the synthesis of (4Z)-Mycophenolate Mofetil (M831455), a degradation product of Mycophenolate mofetil, an immunosuppressant.
Definition
ChEBI: Mycophenolate mofetil is a carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases. It has a role as an immunosuppressive agent, a prodrug, an EC 1.1.1.205 (IMP dehydrogenase) inhibitor and an anticoronaviral agent. It is a gamma-lactone, a member of phenols, an ether, a carboxylic ester and a tertiary amino compound. It is functionally related to a mycophenolic acid and a 2-(morpholin-4-yl)ethanol.
Indications
Mycophenolate mofetil (CellCept), in conjunction with cyclosporine and corticosteroids, has clinical applications in the prevention of organ rejection in patients receiving allogeneic renal and cardiac transplants. By effectively inhibiting de novo purine synthesis, it can impair the proliferation of both T and B lymphocytes. Following oral administration, mycophenolate mofetil is almost completely absorbed from the GI tract, metabolized in the liver first to the active compound mycophenolic acid, and then further metabolized to an inactive glucuronide.
Early clinical trials indicate that mycophenolate mofetil in conjunction with cyclosporine and corticosteroids is a more effective regimen than azathioprine in preventing the acute rejection of transplanted organs. GI side effects are most common.
Trademarks
Cellcept (Roche).
Nebenwirkungen
The main side effects include an increased incidence of herpes zoster, neutropenia, gastrointestinal symptoms, and opportunistic infections. In the transplant literature, 1% to 2% of patients will develop a lymphoproliferative malignancy at the doses recommended for psoriasis. This is a teratogen and should be avoided in women of childbearing age.

Mycophenolate mofetil Upstream-Materialien And Downstream Produkte

Mycophenolate mofetil Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

115007-34-6, Mycophenolate mofetil Verwandte Suche:

Send Inquriy